questionsmedicales.fr
Composés hétérocycliques
Composés hétéromonocycliques
Azirines
Aziridines
1,1',1''-Phosphoryltriaziridine
1,1',1''-Phosphoryltriaziridine : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "1,1',1''-Phosphoryltriaziridine : Questions médicales les plus fréquentes",
"headline": "1,1',1''-Phosphoryltriaziridine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 1,1',1''-Phosphoryltriaziridine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-09",
"dateModified": "2025-04-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "1,1',1''-Phosphoryltriaziridine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Aziridines",
"url": "https://questionsmedicales.fr/mesh/D001388",
"about": {
"@type": "MedicalCondition",
"name": "Aziridines",
"code": {
"@type": "MedicalCode",
"code": "D001388",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.097.217"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Thiotépa",
"alternateName": "Thiotepa",
"url": "https://questionsmedicales.fr/mesh/D013852",
"about": {
"@type": "MedicalCondition",
"name": "Thiotépa",
"code": {
"@type": "MedicalCode",
"code": "D013852",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.097.217.935.960"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "1,1',1''-Phosphoryltriaziridine",
"alternateName": "Triethylenephosphoramide",
"code": {
"@type": "MedicalCode",
"code": "D013721",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Liusheng Huang",
"url": "https://questionsmedicales.fr/author/Liusheng%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "Beth Apsel Winger",
"url": "https://questionsmedicales.fr/author/Beth%20Apsel%20Winger",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, University of California San Francisco."
}
},
{
"@type": "Person",
"name": "Vincent Cheah",
"url": "https://questionsmedicales.fr/author/Vincent%20Cheah",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "David Gingrich",
"url": "https://questionsmedicales.fr/author/David%20Gingrich",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "Florence Marzan",
"url": "https://questionsmedicales.fr/author/Florence%20Marzan",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cerium oxide nanozymes confer a cytoprotective and bio-friendly surface micro-environment to methacrylate based oro-facial prostheses.",
"datePublished": "2023-02-22",
"url": "https://questionsmedicales.fr/article/36848780",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biomaterials.2023.122063"
}
},
{
"@type": "ScholarlyArticle",
"name": "Implantable microfluidics: methods and applications.",
"datePublished": "2023-09-25",
"url": "https://questionsmedicales.fr/article/37698090",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1039/d3an00981e"
}
},
{
"@type": "ScholarlyArticle",
"name": "Appropriate Use of Implants in the Nose.",
"datePublished": "2024-07-22",
"url": "https://questionsmedicales.fr/article/39341678",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.fsc.2024.06.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Era of Biomaterials: Smart Implants?",
"datePublished": "2023-07-12",
"url": "https://questionsmedicales.fr/article/37437296",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acsabm.3c00284"
}
},
{
"@type": "ScholarlyArticle",
"name": "Facial Implants in Male Rejuvenation.",
"datePublished": "2024-04-30",
"url": "https://questionsmedicales.fr/article/38936993",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.fsc.2024.02.008"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Azirines",
"item": "https://questionsmedicales.fr/mesh/D001389"
},
{
"@type": "ListItem",
"position": 5,
"name": "Aziridines",
"item": "https://questionsmedicales.fr/mesh/D001388"
},
{
"@type": "ListItem",
"position": 6,
"name": "1,1',1''-Phosphoryltriaziridine",
"item": "https://questionsmedicales.fr/mesh/D013721"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 1,1',1''-Phosphoryltriaziridine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 1,1',1''-Phosphoryltriaziridine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 1,1',1''-Phosphoryltriaziridine",
"description": "Comment diagnostiquer une exposition au Triethylenephosphoramide ?\nQuels tests sont utilisés pour évaluer la toxicité ?\nQuels symptômes indiquent une intoxication ?\nY a-t-il des marqueurs biologiques spécifiques ?\nComment évaluer les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Prostheses+and+Implants&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quels sont les symptômes d'une exposition aiguë ?\nPeut-on avoir des symptômes neurologiques ?\nQuels symptômes digestifs peuvent apparaître ?\nY a-t-il des symptômes cutanés associés ?\nComment les symptômes évoluent-ils dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Prostheses+and+Implants&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 1,1',1''-Phosphoryltriaziridine",
"description": "Comment prévenir l'exposition au Triethylenephosphoramide ?\nQuelles formations sont nécessaires pour les travailleurs ?\nQuels sont les protocoles de sécurité recommandés ?\nComment gérer les déchets contenant ce composé ?\nY a-t-il des recommandations pour les laboratoires ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Prostheses+and+Implants&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quel est le traitement principal en cas d'intoxication ?\nDes antidotes existent-ils pour ce composé ?\nComment traiter les symptômes neurologiques ?\nQuelles mesures de soutien sont recommandées ?\nY a-t-il des traitements spécifiques pour les effets chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Prostheses+and+Implants&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quelles complications peuvent survenir après exposition ?\nY a-t-il des risques de cancer associés ?\nComment les complications sont-elles surveillées ?\nLes complications peuvent-elles être réversibles ?\nQuels sont les effets à long terme possibles ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Prostheses+and+Implants&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 1,1',1''-Phosphoryltriaziridine",
"description": "Qui est le plus à risque d'exposition ?\nQuels environnements augmentent le risque ?\nY a-t-il des facteurs génétiques impliqués ?\nComment l'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Prostheses+and+Implants&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une exposition au Triethylenephosphoramide ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique d'exposition et des tests biologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la toxicité ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses d'urine peuvent détecter des métabolites toxiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une intoxication ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vomissements et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme les enzymes hépatiques peuvent indiquer une toxicité."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets à long terme ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers et des évaluations cliniques sont nécessaires pour détecter des effets chroniques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une exposition aiguë ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes aigus incluent des maux de tête, des vertiges et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques comme des convulsions peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels symptômes digestifs peuvent apparaître ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des nausées, vomissements et diarrhées sont fréquents après exposition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées et des irritations peuvent se manifester après contact."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps si l'exposition se poursuit."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition au Triethylenephosphoramide ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection individuelle et suivre les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles formations sont nécessaires pour les travailleurs ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des formations sur la manipulation sécurisée des produits chimiques sont essentielles."
}
},
{
"@type": "Question",
"name": "Quels sont les protocoles de sécurité recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les protocoles incluent des procédures d'urgence et des contrôles d'exposition réguliers."
}
},
{
"@type": "Question",
"name": "Comment gérer les déchets contenant ce composé ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les déchets doivent être éliminés selon les réglementations en vigueur pour les produits toxiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les laboratoires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les laboratoires doivent avoir des systèmes de ventilation et des douches de sécurité."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal en cas d'intoxication ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est l'élimination de l'exposition et le soutien symptomatique."
}
},
{
"@type": "Question",
"name": "Des antidotes existent-ils pour ce composé ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique."
}
},
{
"@type": "Question",
"name": "Comment traiter les symptômes neurologiques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes neurologiques peuvent nécessiter des médicaments anticonvulsivants."
}
},
{
"@type": "Question",
"name": "Quelles mesures de soutien sont recommandées ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins de soutien, comme l'hydratation et le monitoring, sont essentiels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les effets chroniques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements des effets chroniques incluent la réhabilitation et le suivi médical."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après exposition ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles hépatiques, rénaux et neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut augmenter le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles surveillées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens médicaux réguliers et des tests de fonction organique sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement précoce."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme peuvent inclure des troubles chroniques et des déficits fonctionnels."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs dans l'industrie chimique et les laboratoires sont les plus à risque."
}
},
{
"@type": "Question",
"name": "Quels environnements augmentent le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les environnements de travail mal ventilés et non sécurisés augmentent le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs génétiques peuvent influencer la susceptibilité à la toxicité."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent être plus vulnérables aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hépatiques ou rénales augmentent le risque."
}
}
]
}
]
}
Poly-(methyl methacrylate) (PMMA) is the preferred biomaterial for orofacial prostheses used for the rehabilitation of naso-palatal defects. However, conventional PMMA has limitations determined by th...
Implantable microfluidics involves integrating microfluidic functionalities into implantable devices, such as medical implants or bioelectronic devices, revolutionizing healthcare by enabling personal...
Alloplastic materials are well suited for use in rhinoplasty in the right clinical scenarios, specifically in patients with platyrrhine noses and in challenging revision cases. The most commonly used ...
Conditions, accidents, and aging processes have brought with them the need to develop implants with higher technology that allow not only the replacement of missing tissue but also the formation of ti...
Many different methods achieve male facial augmentation. Arranged from shorter- to longer-term results, these methods include filler, fat/tissue grafting, fat/tissue transposition, and alloplastic imp...
Silicone tube implantation in lymphoedema reduces symptoms by improving fluid drainage. Although there are descriptions of implant host reaction that can be misdiagnosed as graft infections these are ...
A 34 year old female with lymphoedema of the lower limb, underwent silicone tube implantation. Ten months after surgery, the patient presented with fever and dermatolymphangioadenitis of the limb. Ult...
Sudden onset and improvement of the patient's condition after a short cycle of antibiotics without the need of tube removal supports a host-like reaction rather than an actual infection. Doctors shoul...
This "How I Do It" report describes modifications made to the OSIA bone conduction hearing implant surgery in order to reduce wound complications. Laryngoscope, 132:1850-1854, 2022....
Infections occurring around implants are divided into marginal peri-implantitis and retrograde peri-implantitis (RPI). Marginal peri-implantitis starts in the crestal bone and progresses to the apical...
Medical devices are used in almost all orthopedic surgical subspecialties, and the frequency of adverse events is increasing, which should not be ignored. To provide suggestions on how to avoid implan...
The research extracted recalls of osteosynthesis implants and joint replacement implants from January 1, 2011, to June 30, 2021, in the CNMPA, FDA, HC and ATGA websites and collected the information o...
A total of 315 cases of osteosynthesis implants and 286 cases of joint replacement implants were reported in China, the USA, Canada and Australia. The recalls number from 2016 to 2021 was more than th...
To avoid the recalls of such implants, manufacturers should strictly select implant materials and components, develop detailed labels and instructions, severely control the packaging process and estab...
This retrospective research was directed to investigate the longevity and maintenance requirements of implant-supported prostheses in subjects treated at a tertiary care center....
Patient records of individuals who received implant-supported prostheses between January 2018 and December 2020 were retrospectively analyzed. Demographic information, implant type, prosthetic design,...
The research included 150 subjects with an average follow-up duration of 3 years. The overall survival rate of implant-supported prostheses was 90%, with 20% requiring maintenance interventions. Commo...
Implant-supported prostheses demonstrated a high overall longevity rate, with a subset of subjects requiring maintenance interventions due to complications. Peri-implantitis, prosthetic fracture, and ...